To identify mechanisms of resistance to ALK inhibitors in ALK-positive NB that involve bypass signaling, we conduct genome-wide CRISPR activation (CRISPRa) screens26 in the NB cell lines SH-SY5Y (ALKF1174L) and CHLA-20 (ALKR1275Q) under treatment with brigatinib or ceritinib for 14 days. The gene discussed is ALK; the disease is neuroblastoma.